09441043 is referenced by 1 patents and cites 96 patents.

The present invention provides compositions and methods of use of anti-IGF-1R antibodies or antibody fragments. Preferably the antibodies bind to IGF-1R but not IR; are not agonists for IGF-1R; do not block binding of IGF-1 or IGF-2 to isolated IGF-1R, but effectively neutralize activation of IGF-1R by IGF-1 in intact cells; and block binding of an R1 antibody to IGF-1R. The antibodies may be murine, chimeric, humanized or human R1 antibodies comprising the heavy chain CDR sequences DYYMY (SEQ ID NO:1), YITNYGGSTYYPDTVKG (SEQ ID NO:2) and QSNYDYDGWFAY (SEQ ID NO:3) and the light chain CDR sequences KASQEVGTAVA (SEQ ID NO:4), WASTRHT (SEQ ID NO:5) and QQYSNYPLT (SEQ ID NO:6). Preferably the antibodies bind to an epitope of IGF-1R comprising the first half of the cysteine-rich domain of IGF-1R (residues 151-222). The anti-IGF-1R antibodies may be used for diagnosis or therapy of various diseases such as cancer.

Title
Methods of treating cancer with antibodies that target the insulin-like growth factor type I receptor (IGF-1R)
Application Number
14/598664
Publication Number
9441043 (B2)
Application Date
January 16, 2015
Publication Date
September 13, 2016
Inventor
David M Goldenberg
Mendham
NJ, US
Michele J Losman
South Orange
NJ, US
Chien Hsing Chang
Downingtown
PA, US
Agent
Richard A Nakashima
Assignee
Immunomedics
NJ, US
IPC
C07K 14/475
C07K 14/705
C07K 16/30
A61K 31/69
A61K 45/06
G01N 33/574
A61K 51/10
A61K 47/48
A61K 31/7068
C07K 16/28
A61K 39/395
A61P 35/00
View Original Source